vs
Dominari Holdings Inc.（DOMH）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Dominari Holdings Inc.的1.2倍（$35.5M vs $30.1M），RECURSION PHARMACEUTICALS, INC.净利率更高（-304.2% vs -438.1%，领先133.9%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 220.4%），过去两年Dominari Holdings Inc.的营收复合增速更高（369.1% vs 60.5%）
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
DOMH vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.2倍
$30.1M
营收增速更快
RXRX
高出461.3%
220.4%
净利率更高
RXRX
高出133.9%
-438.1%
两年增速更快
DOMH
近两年复合增速
60.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $30.1M | $35.5M |
| 净利润 | $-131.8M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -8.9% | -304.8% |
| 净利率 | -438.1% | -304.2% |
| 营收同比 | 220.4% | 681.7% |
| 净利润同比 | -12426.2% | 39.6% |
| 每股收益（稀释后） | $-6.94 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMHRXRX
| Q4 25 | $30.1M | $35.5M | ||
| Q3 25 | $50.8M | $5.2M | ||
| Q2 25 | $34.1M | $19.2M | ||
| Q1 25 | $8.1M | $14.7M | ||
| Q4 24 | $9.4M | $4.5M | ||
| Q3 24 | $4.0M | $26.1M | ||
| Q2 24 | $6.2M | $14.4M | ||
| Q1 24 | $1.4M | $13.8M |
净利润DOMHRXRX
| Q4 25 | $-131.8M | $-108.1M | ||
| Q3 25 | $125.2M | $-162.3M | ||
| Q2 25 | $16.6M | $-171.9M | ||
| Q1 25 | $-32.5M | $-202.5M | ||
| Q4 24 | $1.1M | $-178.9M | ||
| Q3 24 | $-4.2M | $-95.8M | ||
| Q2 24 | $-6.1M | $-97.5M | ||
| Q1 24 | $-5.4M | $-91.4M |
毛利率DOMHRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率DOMHRXRX
| Q4 25 | -8.9% | -304.8% | ||
| Q3 25 | -3.1% | -3327.6% | ||
| Q2 25 | -57.0% | -916.8% | ||
| Q1 25 | -394.6% | -1297.9% | ||
| Q4 24 | 0.4% | -4042.4% | ||
| Q3 24 | -79.1% | -377.1% | ||
| Q2 24 | -44.3% | -697.4% | ||
| Q1 24 | -205.2% | -698.4% |
净利率DOMHRXRX
| Q4 25 | -438.1% | -304.2% | ||
| Q3 25 | 246.4% | -3135.3% | ||
| Q2 25 | 48.7% | -894.2% | ||
| Q1 25 | -400.5% | -1373.3% | ||
| Q4 24 | 11.4% | -3935.5% | ||
| Q3 24 | -104.2% | -367.5% | ||
| Q2 24 | -99.1% | -676.6% | ||
| Q1 24 | -398.0% | -662.4% |
每股收益（稀释后）DOMHRXRX
| Q4 25 | $-6.94 | $-0.17 | ||
| Q3 25 | $7.27 | $-0.36 | ||
| Q2 25 | $1.12 | $-0.41 | ||
| Q1 25 | $-3.02 | $-0.50 | ||
| Q4 24 | $0.21 | $-0.56 | ||
| Q3 24 | $-0.67 | $-0.34 | ||
| Q2 24 | $-1.01 | $-0.40 | ||
| Q1 24 | $-0.91 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $80.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $69.4M | $1.1B |
| 总资产 | $112.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资DOMHRXRX
| Q4 25 | $80.5M | $743.3M | ||
| Q3 25 | $176.2M | $659.8M | ||
| Q2 25 | $28.2M | $525.1M | ||
| Q1 25 | $18.9M | $500.5M | ||
| Q4 24 | $8.2M | $594.4M | ||
| Q3 24 | $7.2M | $427.6M | ||
| Q2 24 | $12.1M | $474.3M | ||
| Q1 24 | $7.1M | $296.3M |
总债务DOMHRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益DOMHRXRX
| Q4 25 | $69.4M | $1.1B | ||
| Q3 25 | $210.2M | $1.0B | ||
| Q2 25 | $88.6M | $919.1M | ||
| Q1 25 | $42.4M | $933.9M | ||
| Q4 24 | $39.9M | $1.0B | ||
| Q3 24 | $38.3M | $524.6M | ||
| Q2 24 | $42.4M | $584.4M | ||
| Q1 24 | $47.7M | $401.2M |
总资产DOMHRXRX
| Q4 25 | $112.9M | $1.5B | ||
| Q3 25 | $223.4M | $1.4B | ||
| Q2 25 | $109.3M | $1.3B | ||
| Q1 25 | $52.3M | $1.3B | ||
| Q4 24 | $47.1M | $1.4B | ||
| Q3 24 | $43.4M | $726.5M | ||
| Q2 24 | $49.1M | $775.9M | ||
| Q1 24 | $52.2M | $557.8M |
负债/权益比DOMHRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流DOMHRXRX
| Q4 25 | $22.7M | $-46.1M | ||
| Q3 25 | $-4.9M | $-117.4M | ||
| Q2 25 | $-353.0K | $-76.4M | ||
| Q1 25 | $1.2M | $-132.0M | ||
| Q4 24 | $-16.7M | $-115.4M | ||
| Q3 24 | $-4.7M | $-59.2M | ||
| Q2 24 | $1.4M | $-82.2M | ||
| Q1 24 | $-8.6M | $-102.3M |
自由现金流DOMHRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率DOMHRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度DOMHRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率DOMHRXRX
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
RXRX
暂无分部数据
